Why BioHarvest Sciences Inc.’s (BHST) Stock Is Down 10.70%
As of Tuesday, July 21, BioHarvest Sciences Inc.’s BHST share price has dipped by 10.70%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science-based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional food and beverages, as well as the manufacturing, marketing, and sale of science-based health, pharmaceutical, and cosmeceutical solutions. The company also provides contract development and manufacturing operation services. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red wine. The company has a strategic collaboration with Tate & Lyle plc for the development of plant-based sweetener molecules. The company is based in Vancouver, Canada.
Commentary & Analysis
Why BioHarvest Sciences Inc.’s (BHST) Stock Is Up 7.17%
As of Wednesday, July 15, BioHarvest Sciences Inc.’s BHST share price has surged by 7.17%, which has investors questioning if this is right time to sell.Michael Rose
Why BioHarvest Sciences Inc.’s (BHST) Stock Is Up 6.63%
As of Tuesday, June 30, BioHarvest Sciences Inc.’s BHST share price has surged by 6.63%, which has investors questioning if this is right time to sell.Jenna Brashear
Why BioHarvest Sciences Inc.’s (BHST) Stock Is Up 16.54%
As of Thursday, June 25, BioHarvest Sciences Inc.’s BHST share price has surged by 16.54%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why BioHarvest Sciences Inc.’s (BHST) Stock Is Up 7.07%
As of Wednesday, June 24, BioHarvest Sciences Inc.’s BHST share price has surged by 7.07%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | BHST | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $49.0 | $337.9 | 16% |
|
| Shares Out (Mil) | 22.7 | 27.3 | 32% |
|
| Institutional Ownership | 35.6% | 55.3% | 15% |
|
| Float (Mil) | 19.3 | 30.7 | 28% |
|
| Beta | 1.34 | 0.56 | 77% |
|
| Avg Daily Volume (000s) | 74 | 150 | 32% |
|
| Price Change (52-week) |
(70.9%) | 56.7% | 9% |
|
| Growth | BHST | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 143.9% | 2.3% | 99% |
|
| Net Income (5yr) | (11.0%) | (4.8%) | 28% |
|
| EPS (5yr) | 2.3% | 2.3% | 34 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 65.6% | (13.2%) | 96% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.118) | ($0.408) | ($0.165) | |
| Month Ago EPS | ($0.118) | ($0.408) | ($0.165) | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($0.095) | ($0.325) | ($0.085) | |
| Year/Year Chg | 0.9% | (32.6%) | (166.9%) | |
| Financials | BHST | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $35 | $421 | 17% |
|
| Net Income (TTM) (Mil) | ($11) | $0 | 28% |
|
| EPS (TTM) | ($0.579) | $0.100 | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | $12 | 22% |
|
| Net Cash Flow (TTM) (Mil) | $16 | $0 | 61% |
|
| Long-Term Debt (Q1) (Mil) | $11 | $44 | 29% |
|
| Enterprise Value (Q1) (Mil) | $68 | $334 | 18% |
|
| Valuation | BHST | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.12 | 2.05 | 53% |
|
| P/E | na | 16.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.7 | na |
|
| Ratios | BHST | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 59.5% | 64.3% | 72% |
|
| Net Margin | (32.5%) | 1.6% | 14% |
|
| ROA | (31.7%) | 1.3% | 16% |
|
| ROE | (103.3%) | 5.3% | 9% |
|
| Liabilities to Assets | 49.5% | 48.0% | 41% |
|
| F-Score | 5 | 4 | 51% |
|
BioHarvest Sciences Inc. did not pass any screens on 7/31/2026.
